Atorvastatin for the Treatment of Plaque-type Psoriasis

Toktam Faghihi, Mania Radfar, Zohre Mehrabian, Amir Hoshang Ehsani, and Mohsen Rezaei Hemami,


Pharmacotherapy. 2011;31(11):1045-1050. 

In This Article


Atorvastatin 40 mg/day was not significantly more effective than placebo in the treatment of plaque-type psoriasis in patients with baseline PASI scores less than 12 and receiving standard topical psoriasis therapy. Any therapeutic benefit was attributed to the effects of emollients and the topical therapies applied concomitantly. The lack of significant effect from atorvastatin could be attributed to the patient population, which had relatively low baseline PASI scores. Additional trials are needed to elucidate the place of atorvastatin and other statins for the treatment of psoriasis. We propose a larger follow-up study as well as testing atorvastatin in a more severely affected group characterized by high PASI scores. Further testing with atorvastatin in high doses, rather than standard doses, or in a dose-ranging study is recommended.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.